Phase I/II Study of MDK-703 as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)
Summary
The purpose of this phase I/II study is to evaluate the safety and feasibility of MDK-703 as a monotherapy and combination therapy in patients with advanced or metastatic solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05716295
Study ID: MDK-703-102
Trial Phase: Phase I/II
Trial Sponsor: Medikine, Inc
Therapies Used in This Trial: MDK-703